NOVAVAX, INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 4.09 USD | +3.54% |
|
+3.02% | -14.79% |
| Apr. 15 | Sector Update: Health Care Stocks Gain Monday Afternoon | MT |
| Apr. 15 | Global markets live: Goldman Sachs, Apple, Salesforce, Boeing Tesla... |  |
Financials (USD)
| Sales 2024 * | 846M | Sales 2025 * | 986M | Capitalization | 572M |
|---|---|---|---|---|---|
| Net income 2024 * | -112M | Net income 2025 * | -90M | EV / Sales 2024 * | 0.07 x |
| Net cash position 2024 * | 510M | Net cash position 2025 * | 482M | EV / Sales 2025 * | 0.09 x |
| P/E ratio 2024 * |
-5.66
x | P/E ratio 2025 * |
-103
x | Employees | 1,543 |
| Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 94.33% |
More Fundamentals
* Assessed data
More news
Latest transcript on Novavax, Inc.
More recommendations
More press releases
More news
| 1 day | +3.54% | ||
| 1 week | +3.02% | ||
| Current month | -14.44% | ||
| 1 month | -13.16% | ||
| 3 months | +0.74% | ||
| 6 months | -36.29% | ||
| Current year | -14.79% |
1 week
3.90
4.36
1 month
3.814.95
Current year
3.536.05
1 year
3.5311.36
3 years
3.53277.80
5 years
3.53331.68
10 years
3.53331.68
| Managers | Title | Age | Since |
|---|---|---|---|
John Jacobs
CEO | Chief Executive Officer | 57 | 23-01-22 |
John Trizzino
PSD | President | 64 | 14-03-09 |
James Kelly
DFI | Director of Finance/CFO | 58 | 21-08-15 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Richard Rodgers
BRD | Director/Board Member | 57 | 22-10-28 |
Gregg Alton
BRD | Director/Board Member | 58 | 20-10-31 |
David Mott
BRD | Director/Board Member | 58 | 20-06-15 |
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 0.31% | 18 M€ | +3.79% | - | |
| 0.15% | 0 M€ | 0.00% | - | |
| 0.13% | 2 M€ | -.--% |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-04-26 | 4.09 | +3.54% | 3,021,805 |
| 24-04-25 | 3.95 | -4.82% | 3,380,674 |
| 24-04-24 | 4.15 | -0.95% | 3,000,765 |
| 24-04-23 | 4.19 | +2.95% | 3,600,736 |
| 24-04-22 | 4.07 | +2.52% | 2,302,021 |
Delayed Quote Nasdaq, April 26, 2024 at 04:00 pm EDT
More quotes
Novavax, Inc. is a biotechnology company, which discovers, develops and commercializes vaccines to prevent serious infectious diseases. The Company offers a differentiated vaccine platform that combines a recombinant protein approach, advanced nanoparticle technology and its patented Matrix-M adjuvant to enhance the immune response. It has one commercial program, for vaccines to prevent COVID-19, which includes Nuvaxovid prototype COVID-19 vaccine (NVX-CoV2373 or prototype vaccine) and Nuvaxovid updated COVID-19 vaccine (NVX-CoV2601 or updated vaccine) (collectively, COVID-19 Vaccine). The Company is advancing the development of other vaccine candidates, including its COVID19-Influenza Combination (CIC) vaccine candidate and additional vaccine candidates. Its COVID-19 Vaccine and its other vaccine candidates incorporate the Companyâs proprietary Matrix-M adjuvant to enhance the immune response and stimulate higher levels of functional antibodies and induce a cellular immune response.
Calendar
2024-05-06
- Q1 2024 Earnings Release (Projected)
Related indices
Trading Rating
Investor Rating
ESG Refinitiv
C-
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
6
Last Close Price
4.09
USD
Average target price
15.4
USD
Spread / Average Target
+276.53%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -14.79% | 572M | |
| +1.51% | 42.75B | |
| +8.57% | 41.34B | |
| +49.22% | 41.61B | |
| -12.36% | 26.59B | |
| +8.92% | 25.49B | |
| -25.13% | 18.12B | |
| +29.17% | 12.24B | |
| -3.12% | 11.76B | |
| +6.35% | 11B |
- Stock Market
- Equities
- NVAX Stock
